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Summary 
Background Chronic  inflammation is believed to be a major  mechanism underlying  the pathophysiology of type 2 diabetes. 
Periodontitis is a cause of systemic inflammation. We aimed to assess the effects of periodontal  treatment on glycaemic control in 
people with type 2 diabetes. 
Methods In this 12 month, single-centre, parallel-group, investigator-masked, randomised trial, we recruited  patients 
with type 2 diabetes, moderate-to-severe periodontitis, and at least 15 teeth from four local hospitals and 15 medical or dental practices in the 
UK. We randomly assigned patients (1:1) using a computer-generated table to receive intensive periodontal treatment (IPT; whole mouth 
subgingival scaling, surgical periodontal therapy [if the participants showed good oral hygiene practice; otherwise dental cleaning again], 
and supportive periodontal therapy every 3 months until completion  of the study) or control periodontal  treatment (CPT; supra-gingival  
scaling and  polishing  at the same timepoints as in the IPT group). Treatment allocation included a process of minimisation in terms of 
diabetes onset, smoking  status,  sex, and  periodontitis severity. Allocation to treatment was concealed in  an opaque envelope and 
revealed to the clinician on the day of first treatment. With the exception of dental staff who performed the treatment and clinical 
examinations, all study investigators were masked to group allocation. The primary outcome was between- group difference in HbA,, at 12 
months in the intention-to-treat population. This study is registered with the ISRCTN registry, number ISRCTN83229304. 
Findings Between Oct 1, 2008, and Oct 31, 2012, we randomly assigned  264 patients to IPT (n=133) or CPT (n=131), all 
of whom  were included  in the intention-to-treat population. At baseline,  mean  HbA,, was 8 -1% (SD 1- 7) in  both groups. After 12 
months, unadjusted mean  HbA1, was 8-3% (SE 0- 2) in the CPT group and 7-8%  (0· 2) in the IPT group; with adjustment for baseline 
HbA1,,  age, sex, ethnicity, smoking  status, duration  of diabetes, and BMI, HbA,, was 0-6% (95% Cl 0-3-0- 9; p<0-0001) lower in the IPT 
group than in the CPT group. At least one adverse event was reported in 30 (23%) of133 patients in the IPT group and 23 (18%) of131 
patients in the CPT group. Serious adverse events were reported in 11 (8%) patients in the IPT group, including one (1%) death, and 11 
(8%) patients in the CPT group, including  three (2%) deaths. 
Interpretation  Compared  with CPT, IPT  reduced  HbA1,  in  patients  with type  2 diabetes  and  moderate-to-severe 
periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis 
could be important for effective management of type 2 diabetes. 
Funding Diabetes UK and UK National Institute for Health Research. 
Introduction 
The  worldwide epidemic  of type 2 diabetes is  a major 
cause of disability and premature  mortality, mainly from 
vascular  and  renal   complications.'   Inflammation   can 
affect glycaemic control in patients with diabetes and is 
implicated in atherosclerosis and chronic kidney disease.' 
However, whether  effective control  of  systemic  inflam- 
mation  can  improve  glycaemic control  in  people with 
type 2 diabetes and thereby  reduce their risk of diabetes 
complications remains unclear. 
Periodontitis is a chronic inflammatory  disease, which 
often coexists with diabetes.' It is caused by a dysbiosis of 
the oral microbiota  and is associated with a dysregulated 
immune-inflammatory response.' The response  induced 
by accumulation  of bacteria on the  tooth surface is not 
only confined  to  the  oral cavity, but  is also  associated 
with systemic inflammation.' The elevated systemic 
inflammatory  burden  in  people with  periodontitis  has 
been associated with increased risk of chronic and 
potentially life-threatening diseases including  diabetes, 
cardiovascular disease, and end-stage renal failure! 
Periodontal therapy is usually delivered over three 
phases:  an initial phase, a corrective phase, and  a final 
supportive phase. During the initial phase, any essential 
dental care, oral hygiene advice, and teeth cleaning (scaling 





done. At least 8 weeks after the dental cleaning sessions, 
a  re-evaluation of  the  periodontal  condition  is  done, 
together  with   an   assessment  of   the   patient's   self- 
performed oral hygiene. The  corrective phase of therapy 
includes additional surgical periodontal therapy (if oral 
hygiene is optimum) or a repetition of the scaling and 
root debridement (if oral hygiene is suboptimum). This 
second phase is usually completed within 1-2  months; 
therefore, at around 3 months after the final periodontal 
surgical  session,  a  reassessment  is   done   to  enable 
drugs.9 Furthermore, the  ineffectiveness of non-surgical 
periodontal therapy in  patients with  diabetes has  been 
debated  as   one    of   the   major  confounders  of   the 
association  between the  two  disorders. The   potential 
benefits of periodontitis treatment on  diabetes compli- 
cations therefore remain unknown. 
Our group  previously showed  that  intensive  periodontal 
therapy was needed  to observe  a systemic benefit.l We 
hypothesised that  effective treatment of periodontitis, in 
which   local  and   systemic   inflammation  are   reduced, 
would    improve   glycaemic    control    in   patients    with 
type 2 diabetes,  thereby  enhancing vascular and  renal 
function and quality oflife. 
selection of the  third phase of therapy-   the 
supportive phase. This  final  phase  is an  open-ended protocol   of 
sessions, usually every  3 months, that  includes oral 
hygiene advice  and  professional non-surgical dental 
cleaning as required. 
We  have  previously shown  that   treatment of  perio- 
dontitis  results  in  substantial  reduction  of  systemic 
inflammatory  markers  and   improved  conduit  artery 
endothelial function at 6 months, which  is regarded as 
an  early  indicator of  atherosclerosis.7   Previous studies 
have  investigated the  effect  of  periodontitis treatment 
on    short-term   (2-6    months'   follow-up)    glycaemic 
control    in   patients  with    diabetes,   with    significant 
reductions ofHbA,, ofO·3-0·4 percentage points being 
reported."  However,  these   studies   often    had    low 
numbers  of  participants  and   included  a  mixture  of 
patients with  type 1 and  2 diabetes; some studies were 
done   with   adjuvant  local  or   systemic  antimicrobial 
Methods 
Study design and participants 
We did a 12 month,  single-centre, parallel-group, investi- 
gator-masked, randomised  trial   to  assess   the  effect  of 
intensive  periodontal therapy (non-surgical and  surgical) 
compared with  usual  care  (the  care  provided  at regular 
dental   check-ups-   namely,   cleaning   and   polishing  
the part  of the  tooth  that  is  visible  above the  gingiva). 
We enrolled  consecutive patients  into  the  study  if they 
had type   2  diabetes    (using   WHO   diagnostic   criteria)   
for 
6  months  or  longer,10    moderate-to-severe  periodontitis 
(;o,20  periodontal pockets  with  probing  pocket  depths of 
>4 mm and  marginal alveolar bone loss of >30%), and at 




so  that   eligible  participants  would  present with  active 
signs of gingival inflammation rather  than history of 
breakdown of periodontal soft and  hard  tissues. We 
recruited eligible  participants from among referrals to 
the Eastman Dental Hospital  (Periodontology Unit), 
University College Hospital (outpatients ofthe Department 
of Endocrinology), and Ealing and St Mary's Hospitals in 
London,   UK.  Patients   were  additionally   recruited   from 
15  general   medical   or  dental   practices   in  the  Greater 
London  area  (identified  using  registration data  from the 
Diabetes  Research  Network). Exclusion  criteria  were  un- 
controlled systemic  diseases  other  than  diabetes   (cardio- 
vascular  diseases  [including hypertension], liver diseases, 
pulmonary diseases, end-stage renal failure, or neoplasm); 
hepatitis B or HIV infection; chronic treatment (>2 weeks) 
with drugs known to affect periodontal tissues  (phenytoin 
or ciclosporin); chronic  systemic  antibiotic treatment; and 
pregnancy or lactation. All participants provided  written 
informed consent. The  study  was  approved  by the  joint 
University   College   LondonjUniversity  College   London 
Hospital   Committees  on   Ethics   of   Human    Research 
(Committee A) in November, 2007 (Ref07fH0714j97). The 
original   protocol  was  amended and  re-approved  by  the 
same committee in July, 2008, April, 2010, and  June, 2010. 
A  steering committee  group  met   every  3  months to 
monitor study  progress. The  results  ofthis meeting were 
communicated with  an  independent safety  monitoring 
group, which  reviewed  any  progression of periodontitis 
throughout the trial. No interim analyses were planned. 
which  indicates  unhealed jaw bone  and  possible  abscess 
and pus flow. 
Patients   in  the   IPT  group   received  an  initial   single 
session  of whole mouth scaling ofthe root surfaces under 
local analgesia,  with no time limit  set  for the  duration of 
the session. 2 months after the first whole mouth scaling 
session,   patients  with  good  oral hygiene  (dental  plaque 
scores of ,;20%) and at least one 6 mm or deeper  residual 
periodontal pocket had  periodontal surgical  therapy  to 
improve  access  for  root surface deaning.u Patients  who 
still had suboptimum oral hygiene or did not have residual 
6 mm or deeper  periodontal pockets at 2 months received 
additional scaling  of the  root  surfaces  under local 
analgesia. All patients  in the  IPT  group  subsequently 
received  further sessions of scaling  of the  root surfaces 
under local analgesia  every 3 months until  completion of 
the study. 
Patients   in   the   CPT   group  received   supra-gingival 
scaling  and  polishing of all dentition at the  same  time- 
points as the  IPT group  (after baseline  and at 2, 6, 9, and 
12 months after the completion of the first session of 
periodontal therapy).  At the  end  of the study, patients  in 
the CPT group received any additional periodontal therapy 
that was required. Patients  who showed  progression of 
periodontitis" at any point received prompt  specialist  care 
and were withdrawn from the study. 
Patients  were allocated  to clinicians in a random order 
using  a computer-generated sequence to minimise  treat- 
ment  bias. Diabetes  treatment was managed by the  local 
endocrinology  consultant   and   nurses  using    standard 
clinical guidelines in both groups, and diabetes  clinicians 
were unaware of group assignment throughout the study. 
Patients   were  asked   not   to  discuss   their  study   group 
allocation  with  diabetes  care  professionals or  the  other 
study investigators. Only the treatment clinician discussed 
details  of  the  assigned treatment with  the  patient.  The 
clinical team delivering periodontal therapy in both groups 
included  two  dental  hygienists, two  dentists, and  three 
periodontists  (appendix).   Two  trained  and   calibrated 
examiners  collected   medical   and   dental   histories   at 
baseline,  and   measured  periodontal and   clinical  para- 
meters  at baseline and  at each  study  visit,  as previously 
described.7     Periodontal    parameters   included  gingival 
probing   depth   and   recession  of  the   gingival   margin 
relative  to the  cementa-enamel  junction  at  six sites per 
tooth; presence or absence  ofsupra-gingival dental plaque 
and gingival bleeding on probing;  averaged whole mouth 
number of periodontal lesions (probing  depth of>4 mm); 
and  relative percentages of presence of gingival bleeding 
(full mouth gingival bleeding scores [number of sites with 
gingival  bleeding on  probingjtotal number  of sites  per 
mouthxlOO]) and supra-gingival dental  plaque (full mouth 
plaque  scores  [number of  sites  with  visible  detectable 
plaquejtotal number of  sites  per  mouth x100]). Clinical 
parameters included tobacco exposure (current, former, or 
never smoker) , blood pressure, height, bodyweight, waist 
circumference,  and  body-fat  mass   (data  not   reported). 
Randomisation and masking 
We randomly assigned  patients  (1:1) using  a computer- 
generated table to receive intensive periodontal treatment 
(IPT) or control  periodontal treatment (C PT). Treatment 
allocation  included a process of minimisation,11 taking 
account  of diabetes  duration, smoking status, sex, and 
severity  of periodontitis. Allocation  to treatment  was 
concealed   in  an  opaque   envelope   and   revealed  to  the 
clinician and  patient  on  the  day of first  treatment. With 
the   exception   of  the   study   dental   staff  delivering   the 
treatment and  performing the clinical examinations, all 
other  investigators (vascular examiner, nurses collecting 
anthropometric measures and  blood samples, laboratory 
staff who analysed the serum samples, staff involved with 
the data collection and analyses, and report authors)  were 
masked to the group allocation. 
Procedures 
Essential  dental care, including oral hygiene  instructions 
and  removal of compromised teeth, was done in both  IPT 
and  CPT groups (appendix). Teeth were extracted  if they 
were deemed unsalvageable: ie, if their prognosis was very 
poor despite restorative  efforts, the surrounding jaw bone 
was lost in dose proximity to the tip of the root of the tooth 
(apex) , the  teeth  were  mobile  (grade  Ill),  or there was a 
radiographic translucency around the root tip (possibly on 




biomarkers  (interleukin  1p, interleukin 6, interleukin 8, 
interleukin  10, interleukin 12, interferon y, and tumour 
necrosis factor a [TNFa)) and endothelial cell surface 
markers (E-selectin, P-selectin, intercellular adhesion 
molecule 3, and thrombomodulin) were measured by 
multiplex  assay  (Meso Scale Discovery, Rockville, MD, 
USA; interassay  and intra-assay coefficients of variation 
<7%). Serum creatinine  was measured  on an automated 
analyser  (Cobas 8000). Estimated  glomerular  filtration 
rate (eGFR) was calculated using the four-variable 
Modification in Diet in Renal Disease equation." 
Endothelium-dependent  and endothelium-independent 
flow-mediated dilatation  (FMD) was assessed by ultra- 
sound imaging ofthe brachial artery with a high resolution 
probe (7 MHz), as previously described.16 10 year coronary 
heart disease and stroke risk scores were calculated at 
baseline and at 12 months  using the UK Prospective 
Diabetes Study (UKPDS) Risk Engine. 
Medication  use  was  collected  at  baseline  by  detailed 
interview and  prescription  assessment  and  reviewed at 
study visits using a detailed medication log. Semi- 
quantitative food frequency questionnaires  (detailed 
analyses  taking  into  account  the  basal  metabolic  rate 
are  to   be  reported   elsewhere);  self-reported  data   on 
general health (data not presented); and questionnaires  to 
assess diabetes-related quality of life (Audit of Diabetes 
Dependent Quality ofLife) ,1' oral health (Oral Impacts on 
Daily Performance), and oral health-related quality oflife 
(data not presented) were administered at baseline and at 
12 months. Examiner calibration exercises were repeated 
every 6 months for the duration of the study. 
Fasting blood samples were collected at baseline and at 
study visits. Samples were centrifuged and stored within 
1 h  of  collection.  All plasma  aliquots  were  stored  at 
-70oC for analysis  at the  end  of the  study. HbAk was 
measured  using  liquid chromatography.  Concentrations 
of  glucose,  standard   lipid  fractions   (total  cholesterol, 
HDL cholesterol, LDL cholesterol, and triglycerides), and 
insulin  were  measured   using  standard  assays  and  an 
automated    analyser    (Cobas   8000   analyser,   Roche, 
Mannheim, Germany). Homeostasis Model Assessment 
(HOMA2)  scores   were   calculated.   Serum   C-reactive 
protein (CRP) concentrations were determined by immu- 
noturbidimetry (Cobas Integra 700, Roche, Mannheim, 
Germany).  Full blood  differential  count  was  assessed 
using standard  biochemical tests in real time on the day 
of collection. The  remaining  assays were performed  on 
stored  samples  at the  end  of the  study. Inflammatory 
Outcomes 
The prespecified primary outcome was the difference in 
HbAk between the  IPT and  CPT groups  at 12 months. 
Prespecified secondary endpoints  reported here were 
differences between groups in HbAk at 6 months; glucose, 
insulin, and creatinine concentrations and FMD at 6 and 
12 months; adverse events reported at study visits (defined 
as any changes in anatomical, physiological, or metabolic 
functions occurring in any phase of the clinical study, 
whether or not associated with the study); periodontal 
clinical parameters, lipid fractions , and inflammatory and 
endothelial cell surface markers  at 2, 6, and 12 months; 
and eG FR and  patient-reported outcomes  at 12 months, 
including overall caloric intake and quality oflife (Audit of 
Diabetes Dependent  Quality of Life scores). Prespecified 
secondary outcomes to be reported elsewhere were 
between-group differences in dental plaque composition, 
laser Doppler flowmetry, intima-media thickness, and 
endothelium pulse amplitude tonometry. 
We did post-hoc analyses of the following endpoints: 
between-group differences in  HOMA2 scores at baseline 
and at 6 and 12 months after therapy; between-group 
differences in 10 year cardiovascular risk scores at baseline 
and at 12 months; between-group differences in change in 
diabetes  medications  (including  dose increase  and 
decrease) and systemic antibiotic use from each study visit 
to the next; and whole-group correlation analyses between 
metabolic, inflammatory, kidney, and periodontal para- 
meters at 6 and 12 months. 
Statistical  analysis 
We calculated that a minimum sample size of129 partici- 
pants per group was needed to detect a difference in HbA1, 
of 1 percentage point (SD 2-1) at 12 months  between 
groups,  with an a of 0-05  and 95% power (assuming  a 
10% loss to follow-up). 
Data are reported  as mean  and  SD , unless  otherwise 




dummy  variable), stage  of  study  visit (ie,  at  baseline, 
2 months [if included], 6 months,  and 12 months),  and a 
treatment  time  interaction  term  as explanatory variables 
(covariates).  Additional  covariates  included   age,  sex, 
ethnicity, smoking status, duration of diabetes, and BMI. 
We applied a multilevel model  with random  intercepts, 
which  included  logarithmic  transformation   of the  data 
where appropriate, to all continuous  biomarker outcomes 
(secondary outcomes). A model with random  intercepts 
and unstructured variance-covariance was used  because 
of the  reduced  SEs of within-participant  and  between- 
participant variance to all secondary outcomes. We did not 
adjust  for  multiple  comparisons.   Differences  between 
study groups for primary and secondary outcomes at all 
study follow-up points (2, 6, and 12 months) were adjusted 
for respective baseline values, whereas the absolute values 
for each treatment  group at a given timepoint  were not. 
population  and  used  the  last  measure  carried  forward 
approach for missing values. We repeated the analyses of 
all primary and secondary outcomes using post-hoc 
missing-value analyses with linear digital interpolation. A 
per-protocol population was defined as all participants in 
the    intention-to-treat   population   who   had   at   least 
one  assessment  of efficacy deemed to  be unaffected by 
protocol violations. We did  per-protocol analyses for  all 
outcomes; the estimates derived from these analyses are 
reported for the primary outcome (HbA") and any secon- 
dary or post-hoc outcomes if they differed from estimates 
obtained in the intention-to-treat population. 
We  modelled  the  primary  and  secondary  outcomes 
using multilevel linear regression with the xtmixed 
command in Stata (version 13; StataCorp, College Station, 
TX, USA).17 The models included the respective baseline 
measurement, treatment group (represented by one 
periodontal periodontal 
(n=133) (n=131) 




Intensive   Control 
therapy  therapy 
(Continued from previous column) 
Triglycerides (mmoi!L)                          1-6(1-2)                      1-6 (1-1) 
LDL cholesterol (mmoi!L)                     2-2 (0·9)                      2-4 (0·9) 
HDL cholesterol (mmoi/L)                     1-2 (0·4)                     1·3 (0·4) 
 
eGFR (ml/min  per 1-73 m') 91·0 (22-4) 90-4 (22·5) 
UKPDS 10-year cardiovascular 14·3% (14·5) 15·5% (14·2) 
 
(-reactive protein (mg/L) 1-50 1-80 
(0-90-3-80) (0-80-3·50) 
Interfe ron y (pg/ml)  2·3 (2·7)     3·5 (13·5) 
lnterleukin 10 (pg/ml)  6-8(4·3)     6-9 (5·3) 
lnterleukin 12 (pg/ml)  2-0 (7-1)     7-5 (54·2) 
lnterleukin 6 (pg/ml)  2-0 (1·7)  2·3 (2·0) 
lnterleukin 8 (pg/ml)  15-4 (9·9)   17-0 (12- 2) 
E-selectin (pg/ml)  42-0(34-0)   45·1(39·0) 
P-selectin (pg/ml) 136- 9 (66-3)  139-7 (6 5-4) 
s1CAM3 (pg/m L)  6-2 (8-4)     6-0 (7-9) 
Th rombomodulin (pg!ml)   12- 9 (13-9)   13-4 (14-9) 
Whole mouth plaquescores   74% (18)   75% (18) 
Whole mouth bleeding scores    65% (19)    65% (21) 
Mean periodontal probing depth     3·9 (0-7)    3·9 (0-8) 
(mm) 
Number of peri odo ntal pockets 50 (22) 55 (27) 
 
Percentage of periodontal  34% (16) 35% (16) 
pockets >4 mm 
Number of peri odo ntal pockets 2 6 (24) 24(19) 
>6 mm 
Number of teeth  2 6(4) 26 (4) 
 
Data are mean (SD), n (%),or median (IQR). HOMA2=Homeostasis Model 
Assessment 2. eGFR=est imatedglomerular filtration rate. UKPDS=UK Prospective 
Diabetes Study. siCAM3=soluble intercellular adhesion molecule3. •Heart 
attack, stroke,or hypertension. 
 
Tabl e 1: Baselin e characte risti cs ofth e inten ti on-to -tr eatpopul ati on 
 
Intensive  Control 
periodontal periodontal 
therapy ( n•133)  therapy 
(n=131) 
 
Age (years) 58-2 (9-7) 55·5 (10-0) 
Sex 
Male                                                 82 (62%)                    83 (63%) 
Female                                              51(38%)                    48 (37%) 
Ethnicity 
White                                           43 (32%)                     52 (40%) 
Asian                                                54 (41%)                     43 (33%) 
African                                             25(19%)                     34(26%) 
Other                                                 11(8%)                      2 (2%) 
Smoking history 
Never                                                   75(56%)                     70 (53%) 
Current                                                 18 (14%)                    19 (15%) 
Former                                            40(30%)                     42 (32%) 
Family hi story of cardiovascular diseases* 
Positive  60 (45%)   61(47%) 
Negative 73 (55%) 70 (53%) 
Diabetes duration (years)  8- 3 (7-4)       8-7 (8-4) 
BMI (kg/m') 30 (5) 31(6) 
Waist circumference (cm) 104 (13) 103 (14) 
Systoli c blood pressure (mm Hg)     135 (16)  136 (17) 
Diastolic blood pressure (mm Hg) 82 (10) 83 (9) 
Flow-mediated dil atation   3-9% (2 - 5)   3-9% (2·5) 
HbA,(%)  8-1% (1-7)   8-1% (1-7) 
HbA,(m mol/mol)  64- 6(19-1) 65-4 (18-8) 
Fasting glucose (mmoi!L)  7-8 (6- 5-9-8)    7-8 (6-3-9·7) 
Fasting insulin (miU/L)  12-8 (7-3-20-4)   11-8 (8-0-
19·3) HOMA2-cell function   21-23 (34-13) 19-82 (18-12) 
HOMA2 insulin sensitivity  558-15  585-98 
(848- 23) (904·24) 
HOMA2 insulin resistance  0-37(0-48)     0-38 (0-57) 
Insulin use at baseline 32 (24%)   32 (24% ) 
Insulin daily dose at baseline (IU)  52 (37)   61(42) 
Total cholesterol (mmoi/L) 4·2 (1·0) 4·3 (1-1) 






We did Spearrnan-rank correlation analyses of differences 
in all primary and secondary outcomes. 
We did a post-hoc sensitivity analysis for the  primary 
outcome in subgroups based on use of medications other 
than glucose-lowering drugs. We also did a post-hoc 
subgroup analysis by periodontal treatment subgroup 
(defined as IPT with non-surgical and surgical treatment, 
IPT with non-surgical treatment,  and CPT) assessing the 
differences    between    each   treatment   subgroup  in 
HbAk, CRP and TNFa concentrations, and clinical perio- 
dontal parameters at the 12 month visit. Lastly, we deter- 
mined  the  proportions  of patients in each study group 
who  achieved  either  a  reduction  in  HbAk of at  least 
0·4   percentage   points   or   a   reduction    of   at   least 
0·9 percentage points at 12 months  (X2 comparison). 
For all analyses, a two-sided p value ofless than 0·OS was 
regarded as significant. 
This study was retrospectively registered on the ISRCTN 
registry, number ISRCTN83229304, on June 18, 2010, and 
amended on May 26, 2017. 
anthropometric     differences    between     groups,     and 
participants did not report significant changes in their 
lifestyles or diets (assessed as overall caloric intake) during 
the study. 20 (8%) of264 randomly assigned patients were 
lost  to  follow-up, with similar  proportions  in  the  two 
groups at 12 months  (12 [9%] of133 in the IPT group and 
eight [6%] of131in the CPT group; p=O·5434). Differences in  
some   diabetes  medications   were  seen   at  baseline 
between study groups (appendix). 
After  the  2  month   review visit  (which  was  booked 
2 months  from the initial whole mouth scaling session), 
63 patients with good oral hygiene (dental plaque scores 
of  ,;:20%) and  at  least  one  6  mm  or  deeper  residual 
periodontal pocket had periodontal surgical therapy to 
improve access for root surface cleaning. 55 patients who 
still had suboptimum oral hygiene and 15 patients who did 
not have residual 6 mm or deeper periodontal pockets at 
2 months  received additional scaling of the root surfaces 
under local analgesia (n=70 in total). 
HbAk was reduced  in patients in the  IPT group  after 
12 months  of treatment  compared  with patients  in the 
CPT group  (figure 2). The difference in  HbAk between 
patients in the IPT and CPT groups (adjusted for age, sex, 
ethnicity, smoking status, duration of diabetes,  BMI, and 
baseline HbA,.J was 0· 3% (95% Cl 0·0 to 0·5; p=O·074) at 
6 months and 0·6% (0·3 to 0·9; p<O·0001) at 12 months 
(table 2). Per-protocol analysis showed a non-significant 
difference between groups at 6 months (0·1%, -0·3 to 0·5; 
p=O·6609) and  a  significant  difference  at  12  months 
(0·6%, 0·1 to 1·0; p=0·0101). Post-hoc analyses showed 
that  86 (65%) of 133 patients  in the  IPT group  reached 
a   0·4%   reduction   in   HbAk   at   12  months    versus 
47 (36%) of 131 patients  in  the CPT group  (p=0·0027); 
89 (67%) of133 patients in the IPT group versus 43 (33%) of 
131 patients in the CPT group achieved a 0·9%  reduction 
of HbAk at 12 months  (p=O·0284). A post-hoc sensitivity 
analysis in subgroups  of patients based on use of medi- 
cations other than glucose-lowering drugs confirmed a 
consistent reduction in HbAk in the IPT group compared 
with the CPT group (appendix). 
At 12 months, all clinical periodontal  parameters were 
significantly better in patients  in the  IPT group than in 
patients  in the CPT group  (figure 3). Full mouth  dental 
plaque scores were 18% (95% Cl 13-23; p<O·0001) lower 
at 2 months , 20% (14--25; p<O·0001)  lower at 6 months, 
and  21%  (15-26;  p<O·0001) lower  at  12  months  in 
the   IPT  group  than   in  the  CPT  group.  Full  mouth 
bleeding  scores  were  16% (11-21; p<O·0001) lower  at 
2 months, 24% (19-29; p<O ·0001) lower  at 6 months, 
and 26% (21-31;  p<O ·0001) lower at 12 months in  the 
IPT  group  than   in  the  CPT  group.   Probing  pocket 
depths were 0·6 mm (95% Cl 0·4--0·7; p<0·0001) lower 
at 2 months  and 0·8  mm  (0·6-1·0; p<0·0001) lower at 
both  6 and 12 months after  therapy  in  patients  in  the 
IPT group  than  in the CPT group  (appendix). The  IPT 
group    had    23   (95%   C l   17-28;    p<0·0001)    fewer 
periodontal pockets with a probing  pocket depth greater 
Role ofthe funding source 
The funder of the study had a role in study design, but had 
no role in data collection, data analysis, data interpretation, 
or writing of the  report. The  corresponding  author  had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results 
Between  Oct 1, 2008,  and  Oct  31, 2012, we screened 
1765 patients with type 2 diabetes and randomly assigned 
264  ( 300--6)    of  885   eligible   patients   to   either   I PT 
(n=133) or  CPT (n=131; figure  1). Enrolled participants 
were predominantly  men aged between  30 and 60 years 
(table  1).  Baseline  cardiometabolic  risk  profiles  were 
similar  between  groups  (table 1). There  were no  major 
Rgure 2: HbA" at baseline andfollow·upvisits at 6 and 12 months 
Data are adjusted means and 95% Cls. p-0·5202 for between -group difference 
at 6 months; p-0·0345 for between-group difference at12 months 
(no adjustment for baseline values, but adjusted for age, sex, ethnicity, 
smoking, duration of diabetes, and BM I). CPT-control periodontal treatment 





than  4 mm than  the CPT group at 2 months,  28 (23-34; 
p<O- 0001) fewer at 6 months, and 27 (22-32; p<O- 0001) 
fewer at 12 months. Post-hoc missing data analyses 
confirmed   these  results   (data  not  shown).  The  main 
reason  for  extraction  of unsalvageable  teeth  related  to 
the study hypothesis  was severe infection and 
inflammation, which would affect the study results; 
similar  average  numbers  of teeth  were  removed  from 
each study group  (the mean  number ofteeth  removed 
was 1-0 [95% Cl 0-4--1-2)). 
We  saw  a  significant   reduction  in   plasma  fasting 
glucose concentrations after 6 months  and 12 months  of 
therapy  in the  IPT group compared with the C PT group 
(table  2).  During  the  study,  fasting   insulin  concen- 
trations,  HOMA2 scores, and lipids concentrations did 
not change between  groups  (table 2). We found  no 
differences  in  HbA" between  patients  in the  IPT 
subgroups (non-surgical  [n=70] vs non-surgical  and 
surgical  therapy   [n=63])  in  a  post-hoc   analysis 
(appendix).  Post-hoc  missing  data  analyses  confirmed 
these results (data not shown). 
CRP  concentrations were  significantly  lower  in  the 
IPT group than in the CPT group at 2 months , 6 months, 
and 12 months  after treatment (table 3). TNFa  concen- 
trations  were significantly  lower in the  IPT group than 
in the CPT group  at 6 months and 12 months (table 3; 
appendix) . We did not see significant differences  in any 
other  inflammatory  or  endothelial surface  m  arkers, 
 
2 months 6months  12  months 
 
CPT IPT l'l2M (95% Cl)   pvalue    CPT IPT l'l6M (95% CI) pvalue CPT IPT l'l12M (95% Cl)     pvalue 
 
HbA,(%)  8-1%   8-0%   0-3  0-074   8-3%   7-8%    0-6 <0-0001 
(0-2)  (0-2)  (0-0to 0-5)   (0-2)  (0-2) (0·3 to 0-9) 
Total cholesterol  4·1   4-3    0-1 0-86   4·2   4·3   0-1  0-33   4·1   4·2     0-0  0·99 
(mmoi/L) (0·1) (0·1)  (-0·2 to 0-2)  (0·1)  (0·1)  (-0·1to 0-4)   (0·1) (0·1)  (-0-3 to 0·3) 
HDL cholesterol   1-2  1-3    Q.Q  0-57   1-2   1-3  Q.Q 0-58   1-3    1-3    0-1  0-11 
(mmoi/L) (0-0)  (0-0)  (0-0 to 0-1)  (0-0)  (0-0)  (-0-1to 0-1)  (0-0)  (0-0)  (0-0to 0-1) 
LDL cholesterol   2·2  2-3   0-0  0·71   2-3   2·3   0-1 0-25   2·2  2·2    0-0  0-90 
(mmoi/L) (0·1) (0·1)  (-0-2to 0-2)   (0·1)  (0·1)  (-0·1to 0-3)   (0·1) (0·1)  (-0·2 to 0-2) 
Triglycericles (mmoi/L)  1-5   1-6     Q.Q  0-92   1-5    11  Q.Q 0-77   1-4   1-6   -0-1 0-32 
(0-1) (0-1)  (-0-2 to 0-3)  (0-1)  (0-1)  (-0-4 to 0-3)  (0-1) (0-1) (-0-4 to 0-1) 
Systolic blood pressure    132  131     1·5  0·54  133  131   3·0  0-22  133  130    2·3 0-35 
(mmHg) (1-4)  (1-4) (-3-4 to 6-4)      (1-4)   (1-4) (-1-8 to 7·8)      (1-4)  (1-4) (-2-6to7-2) 
Diastol ic blood 80  80    1-0  0-52  80 81   -0-8 0-57  81 79     1-2 0-43 
pressure (mm  Hg)  (0·9)   (0-9)  (-2-1to 4·2)    (0-8)   (0-8)  (-3-4 to 1-9)    (0·9)   (0·9)  (-11to4-1) 
BMI (kg/m') 30-4 30·1     0-0 0-83  30·5 30·1   0-1  0-62  30·2  30·0     0-0  0-86 
(0·5)  (0·5)  (-0-2to 0-2)    (0·5)   (0·5)  (-0·2 to 0·3)    (0·5)   (0·5)  (-0-4 to 0-4) 
Waistcircumference 104 103    0-6  0-72 103 106  -3-2  0-37  105  104    1-2 0-51 
(cm)   (1-3)  (1·3) (-2-8to4-1)      (2-5)  (2-5)  (-10-2 to 3-8)      (1-3)   (1·3) (-2-3to4-6) 
Fasting insulin (miU/L)  20-3  14-6    4-7  0·13 20-4  19·0  -0-7  0-80  18-0  17-2   -1·1  0-50 
(4-6)  (4-6)  (-1-4 to 10-8)    (4-4)   (4-4)  (-6-3 to4·9)   (3-1)  (3·1)  (-4·2 to 2·0) 
Flow- mediated  3-8%    5-0%  -0-9  <0-0001  3-4%  4-8%   -1-2  <0-0001 
dilatation(%) (0-3) (0·3) (-1-2 to -0- 5)  (0- 2) (0-2) (-1-5 to -0- 9) 
Fasting glucose                                                                                               160-1          148-1           12·1                      0-0323      164-1           151·1              12·9                         0-0344 
(mg/cU..)                                                                                                                 (5·2)                (5·1)       (2-3 to 22·1)                                   (5·2)               (5·1)            (3-4 to 21-0) 
Creatinine (fJmoi/L) 83-1  80-2  1-8  0- 231 83-1 79-8    4-8 0- 0421 
(2·0)   (2-1) (-2·9to 6- 5)   (2-1)  (2-1) (0·1to 9·5) 
eGFR (ml/minper                                                                                                                                                                                 87-1            90-6           -4·1                     0-0031 
1-73 m')                                                                                                                                                                                                                                      (2·4)               (2-6)            (-6- 8to -1-4) 
HOMA2-cell function                                                                                              19- 6           19-6              -1-6                       0-31             17·9               18-7           -1-8                          0-2 9 
(2-3) (2·3) (-4- 6to 1·5)  (1-8) (187) (-5·1to 1·5) 
HOMA2 insulin                                                                                                                    444-7            545-6         -122·1                      0-10          461-8             467-9            0·5                          0·99 
sensitivity                                                                                                                              (53-3)              (53·5)        (-265-8 to 21-5)                           (41·4)              (41-6)            (-89-?to 90-6) 
HOMA2 insulin                                                                                                                         0 -4                  0-5                Q.Q                              0- 57                0-4                  0-4             Q.Q                                   0-14 
resi stance                                                                                                                      (0·1)                (0·1)        (-0·2 to 0-1)                                    (0·0)                (0·0)            (0-0to 0-1) 
UKPD510-year                                                                                                                                                                                                                          11-0%               8-8%             1·1                          0-0323 
cardiova  ular disease                                                                                                                                                                                                         (1-1)                (1-1)            (1-0 to 1-2) 
risk 
 
Data a re unad;usted mean (SE), u nl ess othe rwise stated. p va l ues a re fo rthe cal cul ated l'l val ues, i ncludi ng adjust ment forbaseli n evalues a nd otherconfou nders. CPT=cont rol perio<h ntal t reat me nt 
I PT=intensive pe riodontal treatm ent l'l 2 M=difference at 2 mo nthsbetwee n CPT a nd I PT groups, a djusted for baseli ne values and ot he r co nfou nders. l'l6M=d ifference at 6 month s between CPT a nd I PT groups, 
adjusted fo r basel i ne values a nd othe r confounde rs. l'l12M =di fference at 12 mo nths betwee n CPT and I PT g roups, adjust ed for basel i ne values an d other confou nders. eG FR =est i mat ed gl o me rula rfiltrat io n rate. H 
OMA2=homeostasis model assessment 2  UKPDS= U K P rospect ive Diabetes Study. 
 







Figure 3: Periodontal measures at baseline and follow-up visits at 2, 6, and 12 months 
Data are adjusted meansand 95% Cls. CPT-<:ontrol periodontal treatment IPT-intensive periodontal treatment. *Between-group differences for all peridontal 
measureswere significant at 2, 6, and 12 months (all p<O·OOOl). 
apart   from   a  difference   in   soluble   E-selectin   and 
P-selectin at 6 months (table 3). We saw no differences 
in CRP or TNFa  concentrations between the  lPT 
subgroups in  the  post-hoc  analysis  by corrective 
treatment subgroup (non-surgical  vs non-surgical  and 
surgical; appendix). Post-hoc missing data analyses 
confirmed these results  (data not shown). 
Patients in the lPT group had greater FMD at 6 months 
and 12 months than  patients in the CPT group (table 2). 
We saw no major  differences  between  groups  in blood 
pressure  measures (table 2). Patients  in the  lPT group 
had  a lower overall coronary artery disease 10 year risk 
score  than   patients  in  the  CPT  group  at 12  months 
(table  2).  Post-hoc  missing   data  analyses  confirmed 
these results (data not shown). 
At 12  months ,  creatinine  levels  were  significantly 
lower in patients who received lPT than in patients 
receiving CPT (table 2). At 12 months,  patients  in  the 
lPT  group  had  higher  eGFR than  did  patients  in  the 
C PT group  (table  2) . Post-hoc  missing  data  analyses 
confirmed  these results (data not shown). 
Adverse  events  were  similar   between  study  groups 
(table 4). Four serious  adverse events resulted  in death 
(one  in  the  lPT  group  and  three  in  the  CPT group; p 
0-3683; table 4). Changes  in prescribed  medications 
(>20% of patients)  were similar  between the  two study 
groups (appendix). No significant differences in amount 
and  type  of diabetes  medications   post  randomisation 
were seen between study groups.  Post-hoc missing  data 
analyses confirmed  these results (data not shown). 
Between-group differences in HbA" at 12 months  cor- 
related  with  those  in  periodontal   parameters  (perio- 
dontal probing depth, RO ·2; Spearrnan-rank correlation 
test, pO ·0074;  p coefficient 0·28, 9 5% Cl 0·08 to 0·48), 
kidney  function   (eGFR,  R --0-2;  Spearrnan-rank  cor- 
p  coefficient  -0-19,  95%  Cl relation  test,   pO- 0192; 
-0·28 to  -0·03) ,  and  inflammatory outcomes   (CRP, 
RO ·2; Spearman-rank   correlation    test,    p O- 0014; 
p  coefficient  0-05,  95% Cl  0-01 to  0-08;  and  TNFa, 
R 0-2;    Spearrnan-rank   correlation    test ,    p 0-0013; 
p  coefficient   0-06,  95%  Cl  0-01  to  0-14) . Similarly, 





Results of this study show that IPT improves  metabolic 
control in patients with type 2 diabetes  after 12 months 
compared with usual care. Reductions in HbAk and fast- 
ing  plasma  glucose  concentrations  were accompanied 
by improved vascular and kidney function, reduced sys- 
temic inflammation, and improved quality oflife. These 
results  suggest  a causal  relation  between  periodontitis 
and diabetes control and key complications of diabetes. 
Our  results  suggest  that  oral health  improvement in 
this   population    represents    a   novel   and   important 
therapeutic   opportunity.  Evidence from  other  studies 18 
suggests that every percent age point reduction  in HbAk 
is associated with a 21% reduction  in clinically relevant 
endpoints,   including   mortality.  Metforrnin   represents 
the first-line drug in the management of type 2 diabetes, 
but   most   patients    struggle   to   achieve   meaningful 
improvement   in  metabolic  biomarkers  with  this  drug 
alone. In this study, periodontal  treatment  was used  as 
an  adjunctive  therapy  to  traditional   glucose-lowering 
drugs.  Evidence suggests  that adding  a second  glucose- 
lowering  drug   results   in  an  additional   reduction   in 
HbA,,, ranging between 0·4 and 0·9 percentage points.19 
The effect of intensive periodontal  therapy on metabolic 
control as seen in this study is therefore similar in 
magnitude  to that achieved by adding a second  diabetes 
drug. 
correlated    with    those    in    periodontal    parameters 
(periodontal   probing   depth,   R=O·2;   S pearman-rank 
correlation  test ,  p=0-0062;  p coefficient 0·84,  95% Cl 
0·07  to  1·62) and TNFa (R=0·3;  Spearman-rank 
correlation  test,  p<0-0001; p coefficient 0·22,  95% Cl 
0·10 to 0·54), and  those  of TNFa correlated  with 
periodontal  parameters (periodontal  probing  depth, 
R=O·2;   Spearman-rank   correlation    test,    p=O ·0214; 
p coefficient 0·33, 95% Cl 0· 03 to 0·63). Lastly, changes 
in vascular function (FMD) correlated with improvement 
in  periodontal  parameters (periodontal  probing  depth, 
R=-0·2;   Spearman-rank  correlation   test,   p=O·0033; 
p   coefficient  -0·32,   95%  Cl  -0·56   to  -0·08;   and 
gum   bleeding   scores,   R=-0·2;   Spearman-rank 
correlation  test,  p=0-0142; p coefficient -0·01, 95% Cl 
-0·02 to -0·00). Post-hoc missing  data analyses confir- 
med these results (data not shown). 
Overall Audit of Diabetes Dependent Quality of Life 
scores showed better  quality of life at 12 months in 
patients  in  the  IPT group  than  in  patients  in the CPT 
group  (0·83,  95% Cl  0·29-1·38; p=0-0034). This  was 
mainly due to changes  in working life (difference 1·12, 
95% Cl 0·37-1·86; p=0-0029), self-confidence (differ- 
ence 0·48,  0·17-1·22;  p=0-0413), and living conditions 
(difference 0·81, 0·40-1·43; p=0·0096)  domains ofthe 
test.  Post-hoc  missing   data  analyses  confirmed  these 
results (data not shown). 
 
2 months 6 months 12 months 
 
CPT IPT l'l2M (95%CI)     pvalue CPT IPT l'l6M (95% Cl) pvalue CPT IPT l'l12M (95%CI)      pvalue 
 
CRP(mg/L)   3-7  2-7   1-2  0-0213  4-0   2-8     1-3 0-0102  3-3  2-4     1-0 0-0102 
(0-2)  (0-2)  (1-0 to 1-4)   (0-2)  (0-2)  (0-9to 1-7)   (0-3) (0-2)  (0-8to 1-2) 
TNFa (pg/ml)  4-3   4-4    0-2 0-67   4-6   4-3     0-6  0-0434  4-6   4·1    0-4 0-0201 
(0-3) (0·2)  (-0-4 to 0-8)   (0·2)  (0·2)  (0-0to 1·2)  (0-3) (0·3)  (0-2to 0-6) 
Interferon  y (pg/ml)  2-9   3-4 -1-6 0-14   6-6   2-9     0-8  0-84  2-5  2-6   -0-7 0-37  
(0·5)  (0-5)  (-3-1to 0-2)   (2-1) (2-3)  (-7-0 to 8-6)   (0-4)  (0-5)  (-2-2 to 0-8) 
lnterleukin 10 (pg/ml)  6-9   T3 -0-3 0·57   T3  T3   0-1  0-86  7-6   8-6   -0·1 0-87  
(0-4)  (0-4)  (-1·5to0-8)  (0-4)  (0-4)  (-0-8 to 1·0)   (0-6)  (0-6)  (-1·9to 1-6) 
lnterleukin 12 (pg/ml)  3-2   2-8    0-3 0-79   3·9   2-5    0-8  0-65  3-1   2-7   0-9 0-28 
(1-7) (1-8) (-2-0to 2-6)   (1·9)  (2-1) (-2-6 to 4·1)   (1-7) (1-8) (-0-8to 2-7) 
lnterleukin 6 (pg/ml)  2·0  2-6  -0·9 0-21    2·3  2-3  -0·2  0-61  2·2  3-1  -1-1 0-06  
(0·5)  (0·5)  (-2·3 to 0-5)  (0·2)  (0·2)  (-0-8 to 0·5)   (0·5) (0·5)  (-2·3 to 0-0) 
lnterleukin 8 (pg/ml) 17-2 16-4   0-4  0-89  18.3  16-1    1-1  0-66 17-6  14·9    2-5 0-15 
(2-0)   (2-0)  (-5·1to 5·9)    (1-8)   (1-8)  (-3-lto 5-8)    (1-2)  (1-2) (-0-9 to 6- 0) 
E-selectin (pg/ml) 41·0  35-6  -0-4 0-82  41·9  33·0     3·5  0-0295 43·0  36-8    1·0 0-58 
(3-0)   (2·9)  (-4·2 to 3-3)   (2·7)  (2·7) (0-4 to 6-7)    (2·9)   (2·9)  (-2-4 to 4-4) 
P-selectin  (pg/ml) 139-0 133-0 -0-1  0-99  140-4 119-1   15-0  0-0127 150-1  141-2    42  0-52 
(6-8)    (6-8)  (-13·4 to 13-2)      (6-2)   (6-2)  (3·2 to 26-7)      (7-3)  (7-2) ( -8to17-2) 
siCAM3 (pg/ml)  5·8    5·2 -0·1 0-79    5·9  4·8     0·5  0-06   6-4    5·3   0-4 0-24  
(0·7) (0·7)  (-0-7to 0·5)   (0-6)  (0-6)  (0-0to 0·9)   (0·7) (0·7)  (-0·3 to 1-1) 
lhrombomodulin (pg/ml) 13·4  12-0  -0-4 0-44  13-2  10-7  0-7  0-16  13-6  11-6  0-3  0-52 
(1-3) (1·3) (-1-6 to 0-7) (1-2) (1-2)  (-0-3 to 1-7)  (1-2) (1-2) (-0-6 to 1-2) 
 
Data a re unadjusted mea n (SE), u nl ess otherwise stated. p values a re fo rthe calcul ated t!. values, i ncludi ng adjustme nt forbaseli n eval ues and othe r co nfo u nders. CPT=co ntrol periocl:J ntal treatment 
I PT=intensive pe riodontal treatm ent l'l 2 M=diffe re nce at 2 months betwee n CPT a nd I PT g roups, adjusted for ba seline values a nd other confou nders. l'l6M=d ifference at 6 mo nths between CPT a nd I   PT grou ps, 
ad;usted for basel i ne values a nd othe r confounders. l'l12M =di ffere nce at 12 mo nths betwee n CPT and !PT groups, adjusted fo r basel ine val ues a nd other<o nfou nders. CRP=C- react iveprotein. TN Fa=tumou r 
necrosis facto r a. st CAM3=solue i  ntercellul ar adhesion mol ecul e3. 
 







Many  small   trials   and   several  meta-analyses  have 
investigated  the  potential  benefit  of  periodontitis 
treatment on glucose control, with inconclusive findings. 
Because most  previous  trials  had  a small  sample  size 
(<30 patients per group) and short follow-up, comparison 
with our study is difficult. A previous trial"' of periodontal 
treatment and  metabolic control by Sun  and colleagues 
reported a significant reduction in HbAk ofO·4 percentage 
points  after  3 months. In  the  trial, 157 patients  with 
type 2 diabetes  and  periodontitis  in at least  30% their 
gingival sites were randomly assigned to periodontal 
treatment, including   non-surgical   and  surgical   perio- 
dontal  therapy  and  a  systemic  course  of  antibiotics, 
whereas the 75 participants in the control group received 
no treatment. In our study, we did not measure metabolic 
markers  until 6 months  after baseline, and the IPT and 
CPT groups in our trial were both substantially  different 
to the treatment and control groups, respectively, used in 
the trial by Sun and colleagues. Despite these differences 
and the high risk of bias in the study by Sun and 
colleagues,"' the results  of the study are consistent  with 
our findings. 
Two other  trials21• 22 reported null effects of periodontal 
therapy on metabolic control. In the post-hoc analysis of 
one trial," in which 165 male participants in the  US 
Veterans   Administration  programme    received  perio- 
dontal treatment or usual care for 4 and 12 months  in a 
two-by-two design,  HbAk was numerically  lower in the 
treatment group, but the results were not significant, 
possibly due to the small sample size. Another  6 month 
trial22 of134 patients with periodontitis and type 2 diabetes 
involved a course  of non-surgical  periodontal  therapy, 
but patients randomly assigned to the test group had an 
additional  course  of treatment  after  3 months.  In this 
trial, both  treatment groups  saw a reduction  in  HbAk, 
with   no  significant   difference   between   groups.   The 
smaller sample size, the different periodontal treatments 
provided, and the allocation bias are the main differences 
between our study and this other trial. 
A 2015 Cochrane  review" concluded  that the  level of 
evidence  for  the  effect  of  periodontal   treatment in 
patients  with type 2 diabetes  is of low quality, and that 
any improvement in glucose control after periodontal 
treatment  is  lost  after  3--4 months.  The  largest  trial 
to   date   (the   multicentre   Diabetes   and   Periodontal 
Therapy Trial [DPTT], which had two study groups with 
257   patients    each)"   showed   non-significant    slight 
improvements in  periodontal  health  and  no benefit  on 
glycaemic control at 6 months. Several factors might 
account  for  the  difference  between  our  findings  and 
those of the DPTT. Our study was longer (12 months  vs 
6 months). As in the D PTT, our primary endpoint did not 
reach significance at 6 months, but we did see significant 
differences between  groups  at 12 months.  Additionally, 
participants achieved greater reductions  in dental plaque 
and gingival bleeding scores than  those  reported in the 
DPTT, emphasising the potential importance of control- 
ling periodontal inflammation using effective periodontal 
therapy,  which  would  include  both  non-surgical  and 
surgical   management  of  gum   inflammation  in   the 
patient population. The use of a standardised periodontal 
treatment  protocol in a single specialist centre might have 
strengthened   our   findings;   however,   whether   these 
 
Intensive  Control pvalue 
periodontal  periodontal 
therapy  (n=133)    therapy  (n=131) 
 
Numberofserious 0-8244t 
adverse events (any)* 
21  11(8%)  11(8%) 
22 2 (2%) 1(1%) 
23 1(1%) 1(1%) 
Seriousadverse 1(1%)  3 (2%) 0-3683 
evenls causing deatht 
Number of adverse  0-3994S 
events (any) 
21  30 (23%) 23 (18%) 
22 33 (25%) 38(29%) 
23 17 (13%) 18(14%) 
24 12 (9%) 17 (13% ) 
25  12 (9%) 6 (5%) 
26  7(5%) 3 (2%) 
27 1(1%) 3 (2%) 
28 3 (2%)  1(1%) 
Tooth pain1) 43 (4·0%) 31(3·0%)  0-8910 
Tooth sensitivity1) 33 (3-1% ) 9(0-9%) 0-7327 
Tooth infectionll  27(2-5%)  27(2-6% ) 0-6997 
Vaccination1) 21(2-0%)  24 (2·3%)  0·1376 
Chest infectionll 13 (1-2%) 11(1-0%)  0-5000 
Gum swelli ngll 12 (1-1%) 8(0-8%) 0-1521 
Tooth fracture1) 12(1-1%)  17(1-6%) 0-2271 
Tooth restorationI! 9(0-8%) 12 (1-1%) 0-1332 
HeadacheI] 8(0-8%) 4(0-4%)  0-5578 
InfluenzaI! 7 (O·lo/o) 7 (O·lo/o) 0-3618 
Throat infe<:tion1) 4(0-4%)  5(0·5%) 0-4145 
Foot infectionll  5 (0-5%) 6(0-6%) 0-5488 
Faintingll 3 (0·3%)  3 (0·3%)  0-2733 
Dizzinessll 4(0-4%)  4(0-4%)  0- 5134 
Backpainll  3 (0-3%) 5(0-5%)  0-3882 
 
Data are n (%).*Se rious adverse event s reported i n the i ntensive period:>nt al 
therapy group includetoe gang rene, pneu mo nia, spine su rgety, fall, ea r aceident, 
stroke, gast ric surgery, coronaty a ngiopasty, hypogycaemia, confusio n o r 
d iso rientat ion, l ung resection, k idney stones, and p rostate hype rt rophy;se rious 
adverse events reported i n the control pe riodo ntal therapy group i nclude chest pa i n 
( heartbu rn). hyperte nsive crisis, femoral fracture, pne umonia, alcohol ic l ive r 
disease, acute episode of irritable bowel syndro me, spine su rge<y, and h p 
replacement. tThe p value is a n ove rall compariso n of the nu mbersof all serious 
adverse events between groups. +The seriousadverse eve nt result i ng in death 
reported in the intensive pe riodontal therapy group was acute kidney failure; 
serious adverse event s result i ng i  n death reported i n the control pe riodo ntal 
therapy group were myocardial infa rct on, hea rt fa ilu re, and stroke. SThepva lue is 
an overall co mparison of the numbers of all adverse eve nts (i nclud ing serious 
adverse events) between group> ll Denom inators for calculat ion of pe rcentages are 
total number ofeve nts(n=1064 in the inte nsive pe riodontal therapy g roup; 
n=1048 in the control pe riod:>ntal therapy g roup). 
 





Inflammation  is a known  driver of insulin  resistance, 
with a role in the initiation and evolution of cardiovascular 
and renal complications in patients with and without 
diabetes.28  Our findings support the hypothesis that 
reduction of periodontal inflammation  is associated with 
reduced systemic inflammation and improved vascular 
function and  metabolic markers, as suggested  in a 2015 
systematic review.5  TNFa has been implicated in systemic 
insulin sensitivity,29 and the severity of periodontitis 
correlates linearly with systemic levels ofTNFa in patients 
with diabetes.30  We saw a linear correlation between 
reductions from baseline to 12 months  in markers of 
systemic inflammation  (CRP and TNFa), periodontal 
inflammatory parameters (probing pocket depths, number 
of deeper periodontal pockets, and gingival bleeding), and 
systemic outcomes (metabolic control and vascular and 
kidney functions).  However, these  correlations were not 
seen for measures  of insulin  production  and sensitivity 
(HOMA2 scores). Previous reports have shown that 
reduction of inflammation  by lifestyle interventions''  or 
drug therapy  (eg, interleukin-1 antagonists)" increases 
secretion  of insulin  from  p  cells and  decreases  blood 
glucose concentrations in patients with diabetes. In a large 
secondary prevention trial33  of patients at high risk of 
cardiovascular diseases and other comorbidities including 
type 2 diabetes, treatment with an interleukin-1p inhibitor 
(canakinumab) significantly lowered the rate of recurrent 
cardiovascular events versus placebo; this  result was 
independent  from the reductions in lipids achieved with 
drugs. Whether treatment  of periodontitis, and the 
associated reduction in systemic inflammation,  could 
produce similar benefits on outcomes such as cardio- 
vascular and renal events in patients with type 2 diabetes 
could be addressed in future studies. 
Our   study  has  some  limitations.  In  particular,  our 
findings   could   be  partly  attributed   to  the   effect  of 
non-diabetes medications. Patients in the CPT and IPT 
groups presented with some differences in their use of 
aspirin, p blockers, and angiotensin-II blockers at baseline. 
We cannot exclude that medications used might have 
contributed  to  the  differences  in  HbA,, between  study 
groups at 12 months. However, a post-hoc sensitivity 
analysis in subgroups  of patients not taking these 
medications  lent  support  to  a  consistent  reduction  in 
HbA,, in the  IPT group  compared with the CPT group. 
Future studies should address the efficacy of periodontal 
treatment in patients with type 2 diabetes during treatment 
with different cardiometabolic drugs. We did this study in a 
single university centre and patients with moderate-to- 
severe periodontitis were treated for 12 months.  We 
acknowledge a potential recruitment bias in this study and 
urge  caution in  extrapolating the  results to all patients 
with type 2 diabetes; nevertheless, we aimed to reduce bias 
by recruiting from both hospital and primary-care 
recruitment centres (dental and medical). 
Global prevalence of periodontal diseases is higher than 
50%.  In  people with  diabetes,  the  prevalence of severe 
findings could be replicated in multicentre, larger trials is 
unclear. Finally, our study participants differed from those 
in the DPTT: our participants were aged 18 years or older 
with at least 20 periodontal sites with active periodontal 
inflammation,   whereas  in  the  D PTT, the  patients  were 
aged  35 years or  older  with  a  minimum of two  sites 
with periodontal inflammation. As a result, a smaller 
proportion of patients in the DPTT had gum inflammation 
to start with than in our study. At the end of the  D PTT, 
many of the test patients still had ongoing gum 
inflammation  and  could have been  re-enrolled into the 
same study. 
In our study, we found improvements  in a broad range 
of secondary outcomes, suggesting an effect of periodontal 
therapy on cardiovascular and renal complications of 
diabetes. In a previous randomised clinical trial7 in patients 
without diabetes, we showed that IPT led to significantly 
improved endothelial function after6 months oftreatment. 
We now show that this improvement  can be maintained 
up to 1 year in a population with diabetes who are at high 
risk for cardiovascular disease. Additionally, we report a 
1-1% lower overall UKPDS 10 year risk of cardiovascular 
disease  with  IPT  than  with  CPT at  12  months.  This 
estimate must be interpreted cautiously rather than as 
definitive evidence to be applied in clinical practice. 
Findings  from  the  UKPDS  for  metformin   or  insulin 
versus conventional glucose lowering with diet restriction 
showed  only a marginal  improvement  in cardiovascular 
mortality despite a 0-9% reduction in HbA,/" Periodontal 
treatment  might  improve overall cardiovascular risk 
beyond the  glucose lowering  effect; if demonstrated  in 
larger intervention trials, periodontitis might represent a 
novel preventable cause of vascular complications in 
patients with diabetes. 
The  change  in  HbA" was accompanied  by improved 
eG FR in our study, suggesting  a causal relation between 
periodontitis and increased renal and cardiovascular 
complications, as has been postulated from  at least one 
observational study.25 Glomerular endothelial damage is 
regarded as an early step in the evolution of diabetic 
nephropathy.26   A reduction in the thickness  of the endo- 
thelial glycocalyx has been described in patients with early 
stages  of diabetic  nephropathy!'  and  the  observed 
beneficial effect ofiPT on endothelial function might link 
the improvements  in FMD and renal function that we 
observed. 
The IPT group reported better diabetes-related quality of 
life than the CPT group in our study. A systematic review" 
found that no relevant studies reported data on quality of 
life; a gap partly addressed by our study. Our results 
showed that the overall improvements were mainly due to 
increased  psychological and functional aspects of quality 
of life, with differences  reported in both self-confidence 
and living conditions. Furthermore,  IPT resulted in 
improvement of the working life of patients with diabetes, 





forms  of  periodontitis  is  almost  50%.34    Our  findings 
highlight the potential to improve metabolic control and 
possibly diabetes outcomes by addressing poor oral health 
in  those  with  diabetes.  Longer and  larger  studies  are 
needed to determine whether the benefits we have shown 
are sustained beyond 12 months, are broadly applicable to 
people with type 2 diabetes, can reduce morbidity and 
mortality, and can improve quality oflife in the long term. 
If confirmed in larger trials, diabetes care should incor- 
porate routine  oral health  assessment  and  treatment  as 
part oflifelong disease management. 
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